PUBLISHER: Grand View Research | PRODUCT CODE: 1908144
PUBLISHER: Grand View Research | PRODUCT CODE: 1908144
The global veterinary stem cell therapy market size was estimated at USD 154.07 million in 2024 and is projected to reach USD 311.03 million by 2033, growing at a CAGR of 8.62% from 2025 to 2033. The industry is witnessing significant growth driven by the increasing incidence of chronic and degenerative conditions in pets, continuous advancements in stem cell therapy technologies, rising pet humanization, and a greater willingness among owners to invest in advanced veterinary care.
The market is further supported by the growing demand for advanced, disease-modifying therapies in veterinary care. Stem cell-based drugs provide the unique advantage of relieving clinical symptoms as well as targeting the root cause of many chronic conditions. For instance, VET CELL TECH is helping drive this shift by building a strong pipeline using its own iPSC technology, which allows it to produce stem cell treatments on a large scale with reliable quality and smoother distribution. The company is developing regenerative therapies for major pet health problems like Feline Chronic Gingivostomatitis, chronic kidney disease in cats, atopic dermatitis in dogs, osteoarthritis, and several future conditions. Because these treatments are standardized, scalable, and designed for real clinical needs, they fill important gaps in care for older and chronically sick pets. This is expected to encourage more veterinarians to adopt stem cell therapies and increase overall spending on advanced regenerative care in the market.
In addition, initiatives undertaken to bring advanced, evidence-based regenerative therapies into mainstream veterinary care are significantly shaping market growth. For instance, according to an article published by The Indian Express, in June 2025, Gallant's stem cell therapy for a serious and painful condition in cats is expected to receive U.S. FDA approval in 2026. Getting this approval would be a big step forward, showing that the treatment is safe and truly works, which would boost confidence among veterinarians and pet owners. Once FDA-approved stem cell products become available, more clinics are likely to use them, investors may put more money into the field, and overall acceptance of regenerative treatments would grow, helping push the industry forward.
Furthermore, rising pet spending is giving a strong boost to the industry, because more pet owners now treat their animals like family and are willing to pay for advanced, high-quality medical care to keep them healthy. For instance, according to APPA, the rise in U.S. pet spending from USD 151.9 billion in 2024 to a projected USD 157 billion in 2025 shows that owners are consistently allocating more money toward premium and advanced veterinary care. This growing financial commitment directly supports the adoption of high-value treatments like stem cell therapy, which can be more expensive than traditional options but offer superior outcomes for chronic conditions such as osteoarthritis, dysplasia, and inflammatory diseases.
Global Veterinary Stem Cell Therapy Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary stem cell therapy market report based on product, application, animal type, end-use, and region.